Enzymatica AB (publ) (ENZY.ST)
SEK 3.4
(0.0%)
SEK 3.4
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 31.86 Million SEK | 11.98% |
| 2022 | 28.45 Million SEK | -14.69% |
| 2021 | 33.35 Million SEK | -56.09% |
| 2020 | 75.95 Million SEK | 69.19% |
| 2019 | 44.89 Million SEK | 21.99% |
| 2018 | 36.8 Million SEK | 1.31% |
| 2017 | 36.32 Million SEK | 63.43% |
| 2016 | 22.22 Million SEK | 14.43% |
| 2015 | 19.42 Million SEK | 30.4% |
| 2014 | 14.89 Million SEK | 82.67% |
| 2013 | 8.15 Million SEK | 3242.21% |
| 2012 | 244 Thousand SEK | 941.38% |
| 2011 | -29 Thousand SEK | 0.0% |
| 2009 | -95.09 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 6.43 Million SEK | -36.68% |
| 2024 Q2 | 3.86 Million SEK | -39.98% |
| 2023 Q3 | 8.28 Million SEK | 51.16% |
| 2023 Q4 | 10.16 Million SEK | 22.71% |
| 2023 FY | 31.86 Million SEK | 11.98% |
| 2023 Q1 | 7.93 Million SEK | -27.29% |
| 2023 Q2 | 5.47 Million SEK | -30.99% |
| 2022 Q3 | 10.29 Million SEK | 105.8% |
| 2022 Q4 | 10.91 Million SEK | 6.09% |
| 2022 FY | 28.45 Million SEK | -14.69% |
| 2022 Q1 | 2.24 Million SEK | -82.29% |
| 2022 Q2 | 5 Million SEK | 123.06% |
| 2021 Q2 | 1.78 Million SEK | -80.42% |
| 2021 Q4 | 12.66 Million SEK | 28.94% |
| 2021 FY | 33.35 Million SEK | -56.09% |
| 2021 Q1 | 9.08 Million SEK | -64.99% |
| 2021 Q3 | 9.82 Million SEK | 451.74% |
| 2020 Q1 | 20.95 Million SEK | 23.52% |
| 2020 Q4 | 25.96 Million SEK | 23.51% |
| 2020 Q3 | 21.01 Million SEK | 161.85% |
| 2020 Q2 | 8.02 Million SEK | -61.69% |
| 2020 FY | 75.95 Million SEK | 69.19% |
| 2019 FY | 44.89 Million SEK | 21.99% |
| 2019 Q4 | 16.96 Million SEK | 19.68% |
| 2019 Q2 | 3.98 Million SEK | -59.27% |
| 2019 Q1 | 9.77 Million SEK | -30.78% |
| 2019 Q3 | 14.17 Million SEK | 255.95% |
| 2018 Q4 | 14.12 Million SEK | 52.65% |
| 2018 FY | 36.8 Million SEK | 1.31% |
| 2018 Q3 | 9.25 Million SEK | 240.43% |
| 2018 Q2 | 2.71 Million SEK | -74.62% |
| 2018 Q1 | 10.7 Million SEK | -22.52% |
| 2017 FY | 36.32 Million SEK | 63.43% |
| 2017 Q4 | 13.82 Million SEK | 0.25% |
| 2017 Q1 | 5.98 Million SEK | 1.86% |
| 2017 Q2 | 2.73 Million SEK | -54.27% |
| 2017 Q3 | 13.78 Million SEK | 403.69% |
| 2016 Q2 | 3.1 Million SEK | -39.39% |
| 2016 Q3 | 8.12 Million SEK | 161.86% |
| 2016 Q4 | 5.87 Million SEK | -27.71% |
| 2016 Q1 | 5.12 Million SEK | -28.78% |
| 2016 FY | 22.22 Million SEK | 14.43% |
| 2015 Q3 | 4.57 Million SEK | 72.6% |
| 2015 FY | 19.42 Million SEK | 30.4% |
| 2015 Q4 | 7.19 Million SEK | 57.02% |
| 2015 Q1 | 5 Million SEK | -27.73% |
| 2015 Q2 | 2.65 Million SEK | -46.98% |
| 2014 Q4 | 6.92 Million SEK | 36.51% |
| 2014 Q1 | 1.94 Million SEK | -60.07% |
| 2014 Q3 | 5.07 Million SEK | 427.78% |
| 2014 Q2 | 961 Thousand SEK | -50.46% |
| 2014 FY | 14.89 Million SEK | 82.67% |
| 2013 Q2 | 325 Thousand SEK | -71.96% |
| 2013 Q4 | 4.85 Million SEK | 167.86% |
| 2013 FY | 8.15 Million SEK | 3242.21% |
| 2013 Q3 | 1.81 Million SEK | 458.15% |
| 2013 Q1 | 1.15 Million SEK | 333.4% |
| 2012 FY | 244 Thousand SEK | 941.38% |
| 2012 Q3 | 112.33 Thousand SEK | 250.83% |
| 2012 Q2 | -74.47 Thousand SEK | -18.62% |
| 2012 Q1 | -62.78 Thousand SEK | 0.0% |
| 2012 Q4 | 267.42 Thousand SEK | 138.07% |
| 2011 Q2 | -4926.00 SEK | 0.0% |
| 2011 FY | -29 Thousand SEK | 0.0% |
| 2011 Q3 | 182.59 Thousand SEK | 3806.74% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | -203.58 Thousand SEK | 0.0% |
| 2010 Q3 | -260.57 Thousand SEK | -27.99% |
| 2009 FY | -95.09 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -383.359% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 6793.908% |
| BioGaia AB (publ) | 950.19 Million SEK | 96.647% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 916.791% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 354133.333% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 1618.009% |
| Nanexa AB (publ) | 59.15 Million SEK | 46.138% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -98.734% |
| ODI Pharma AB | -1.34 Million SEK | 2474.938% |
| Orexo AB (publ) | 549.9 Million SEK | 94.206% |
| Probi AB (publ) | 220.21 Million SEK | 85.531% |
| Swedencare AB (publ) | 164.8 Million SEK | 80.666% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 99.773% |
| Toleranzia AB | -919 Thousand SEK | 3567.138% |
| Vivesto AB | -10.65 Million SEK | 399.015% |